Latanoprost/Timolol Eg

Latanoprost, the active ingredient in Latanoprost/Timolol Eg, is a prostaglandin analog and non‑selective beta‑blocker combination presented as eye drops for ocular (topical) use. It treats open‑angle glaucoma and ocular hypertension in adults.

GNH USA supplies Latanoprost/Timolol Eg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Latanoprost/Timolol Eg is indicated for conditions affecting intraocular pressure within the glaucoma and ocular hypertension disease family.

Open‑angle glaucoma: lowers intraocular pressure to prevent optic‑nerve damage. Ocular hypertension: reduces pressure to lower the risk of progression to glaucoma. Elevated intraocular pressure (IOP) in adults: provides additional pressure control when monotherapy is insufficient.

Common Side Effects: - Eye irritation or burning sensation - Transient blurred vision after instillation - Conjunctival hyperemia (redness) - Itching or mild allergic reaction of the eyelid - Dry eye sensation - Increased eyelash length or thickness

Serious or Rare Side Effects: - Severe ocular inflammation or uveitis - Acute allergic reaction with swelling and pain - Sudden loss of vision - Systemic bradycardia or hypotension - Bronchospasm in patients with asthma - Persistent eye pain requiring medical attention

Before using Latanoprost/Timolol Eg, consider the following precautions: - Cardiovascular assessment: monitor heart rate and blood pressure due to beta‑blocker activity. - Respiratory evaluation: avoid in patients with asthma or severe COPD. - Ocular infection: do not use if active eye infection is present. - Diabetes monitoring: beta‑blockers may mask hypoglycaemia symptoms. - Pregnancy and lactation: use only if benefits outweigh potential risks. - Store at ambient temperature: keep in the original pack, protect from moisture and light.

Latanoprost/Timolol Eg may interact with other medicines as follows:

Major Interactions (Avoid): - Systemic beta‑blockers (e.g., propranolol): risk of additive bradycardia. - Asthma or COPD rescue inhalers (beta‑agonists): may reduce bronchodilator efficacy. - Other ocular beta‑blocker drops: excessive intraocular pressure reduction.

Moderate Interactions (Monitor Closely): - Topical non‑steroidal anti‑inflammatory drugs: increased ocular irritation. - Carbonic anhydrase inhibitor eye drops: additive IOP‑lowering effect. - Systemic antihypertensive agents: monitor for hypotension.